M
Meenal Datta
Researcher at Harvard University
Publications - 37
Citations - 2644
Meenal Datta is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Tumor microenvironment. The author has an hindex of 14, co-authored 24 publications receiving 1623 citations. Previous affiliations of Meenal Datta include Tufts University.
Papers
More filters
Journal ArticleDOI
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
Jessica A. Carr,Daniel Franke,Justin R. Caram,Collin F. Perkinson,Mari Saif,Vasileios Askoxylakis,Meenal Datta,Meenal Datta,Dai Fukumura,Rakesh K. Jain,Moungi G. Bawendi,Oliver T. Bruns +11 more
TL;DR: Indocyanine green, a clinically approved near-IR dye, exhibits a remarkable amount of SWIR emission, which enables state-of-the-art SWIR imaging with direct translation potential into clinical settings, and even outperforms other commercially available SWIR emitters.
Journal ArticleDOI
Solid stress and elastic energy as measures of tumour mechanopathology
Hadi Tavakoli Nia,Hao Liu,Giorgio Seano,Meenal Datta,Meenal Datta,Dennis Jones,Nuh N. Rahbari,Joao Incio,Vikash P. Chauhan,Keehoon Jung,John D. Martin,Vasileios Askoxylakis,Timothy P. Padera,Dai Fukumura,Yves Boucher,Francis J. Hornicek,Alan J. Grodzinsky,James W. Baish,Lance L. Munn,Rakesh K. Jain +19 more
TL;DR: Two-dimensional spatial mappings of solid stress and the resulting elastic energy in excised or in situ tumours with arbitrary shapes and wide size ranges can be obtained via three distinct and quantitative techniques that rely on the measurement of tissue displacement after disruption of the confining structures.
Journal ArticleDOI
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper,Lars Riedemann,Zohreh Amoozgar,Giorgio Seano,Katharina Susek,Veronica Yu,Nisha Dalvie,Robin L. Amelung,Meenal Datta,Jonathan W. Song,Vasileios Askoxylakis,Jennie Taylor,Christine Lu-Emerson,Ana Batista,Nathaniel D. Kirkpatrick,Keehoon Jung,Matija Snuderl,Alona Muzikansky,Kay Stubenrauch,Oliver Krieter,Hiroaki Wakimoto,Lei Xu,Lance L. Munn,Dan G. Duda,Dai Fukumura,Tracy T. Batchelor,Rakesh K. Jain +26 more
TL;DR: It is shown that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels.
Journal ArticleDOI
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Teresa Peterson,Nathaniel D. Kirkpatrick,Yuhui Huang,Christian T. Farrar,Koen A. Marijt,Jonas Kloepper,Meenal Datta,Zohreh Amoozgar,Giorgio Seano,Keehoon Jung,Walid S. Kamoun,Trupti Vardam,Matija Snuderl,Jermaine Goveia,Sampurna Chatterjee,Ana Batista,Alona Muzikansky,Ching Ching Leow,Lei Xu,Tracy T. Batchelor,Dan G. Duda,Dai Fukumura,Rakesh K. Jain +22 more
TL;DR: Dual inhibition of VEGFR/Ang-2 prolongs survival in preclinical GBM models by reducing tumor burden, improving normalization, and altering TAMs, which may represent a potential therapeutic strategy to overcome the limitations of anti-VEGFR monotherapy in GBM patients.
Journal ArticleDOI
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta,Kohei Shigeta,Meenal Datta,Tai Hato,Tai Hato,Shuji Kitahara,Ivy X. Chen,Aya Matsui,Hiroto Kikuchi,Emilie Mamessier,Shuichi Aoki,Shuichi Aoki,Rakesh R. Ramjiawan,Rakesh R. Ramjiawan,Hiroki Ochiai,Nabeel Bardeesy,Peigen Huang,Mark Cobbold,Andrew X. Zhu,Rakesh K. Jain,Dan G. Duda +20 more
TL;DR: Combining PD‐1 blockade with antiangiogenesis has shown promise in substantially increasing the fraction of patients with HCC who respond to treatment, but the mechanism of this interaction is unknown.